- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Neuromyelitis Optica.
Displaying page 1 of 1.
EudraCT Number: 2013-001150-10 | Sponsor Protocol Number: ECU-NMO-301 | Start Date*: 2013-12-12 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO) | |||||||||||||
Medical condition: Neuromyelitis Optica | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Completed) GB (Prematurely Ended) ES (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) FR (Completed) HR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001151-12 | Sponsor Protocol Number: ECU-NMO-302 | Start Date*: 2013-12-12 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO) | |||||||||||||
Medical condition: Neuromyelitis Optica | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) ES (Completed) AT (Completed) CZ (Completed) DK (Completed) FR (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005431-41 | Sponsor Protocol Number: BN40900(SA-309JG) | Start Date*: 2017-10-16 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and... | |||||||||||||
Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) RO (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004092-39 | Sponsor Protocol Number: WN41733 | Start Date*: 2022-03-23 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE PHARMACOKINETICS, EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH AQP4 ANTIBODY ... | ||||||||||||||||||
Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003752-21 | Sponsor Protocol Number: BN40898(SA-307JG) | Start Date*: 2014-05-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with neuromyelitis... | |||||||||||||
Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Ongoing) PL (Completed) HU (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002335-34 | Sponsor Protocol Number: STRiVE | Start Date*: 2014-10-30 | ||||||||||||||||
Sponsor Name:Guy's and St Thomas NHS Foundation Trust | ||||||||||||||||||
Full Title: A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children | ||||||||||||||||||
Medical condition: Transverse myelitis (TM) (acute, first onset cases), including first presentation of neuromyelitis optica (NMO) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000253-36 | Sponsor Protocol Number: CD-IA-MEDI-551-1155 | Start Date*: 2014-12-08 | |||||||||||
Sponsor Name:MedImmune LLC | |||||||||||||
Full Title: A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disord... | |||||||||||||
Medical condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended) EE (Prematurely Ended) BG (Completed) PL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) GR (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001088-26 | Sponsor Protocol Number: MN42928 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | |||||||||||||
Full Title: SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION | |||||||||||||
Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000529-30 | Sponsor Protocol Number: 33 | Start Date*: 2013-11-27 |
Sponsor Name:Walton Centre Foundation Trust | ||
Full Title: A pilot study to assess efficacy of prolonged-Release oral fampridine on ambulation and visual function in Neuromyelitis Optica | ||
Medical condition: Neuromyelitis optica (NMO) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003528-33 | Sponsor Protocol Number: VIB0551.P2.S2.NMO | Start Date*: 2022-04-13 | |||||||||||
Sponsor Name:Horizon Therapeutics Ireland DAC | |||||||||||||
Full Title: An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder | |||||||||||||
Medical condition: Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO]) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) SE (Trial now transitioned) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003413-35 | Sponsor Protocol Number: WN42349 | Start Date*: 2020-12-07 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) | |||||||||||||
Medical condition: Neuromyelitis Optic Spectrum Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Ongoing) BG (Ongoing) PL (Completed) IT (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006075-42 | Sponsor Protocol Number: ALXN1210-NMO-317 | Start Date*: 2022-05-17 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents Wit... | |||||||||||||
Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003352-37 | Sponsor Protocol Number: ALXN1210-NMO-307 | Start Date*: 2020-06-08 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) | |||||||||||||
Medical condition: Neuromyelitis Optica Spectrum Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) AT (Completed) PL (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001829-26 | Sponsor Protocol Number: ECU-NMO-303 | Start Date*: 2019-12-18 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder | |||||||||||||
Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001512-28 | Sponsor Protocol Number: COVIM | Start Date*: 2021-05-11 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: Immunogenicity of COVID-19 vaccines in medical staff and special risk populations | |||||||||||||
Medical condition: SARS-CoV-2 immunogenicity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.